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Open Forum Infectious Diseases
MAJOR ARTICLE

Risk Factors for Surgical Site Infection After
Cholecystectomy
1

Division of Infectious Diseases, Department of Medicine, 2Department of Surgery, and 3Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine,
St. Louis, Missouri; and 4HealthCore, Inc., Wilmington, Delaware

Background. There are limited data on risk factors for surgical site infection (SSI) after open or laparoscopic cholecystectomy.
Methods. A retrospective cohort of commercially insured persons aged 18–64 years was assembled using International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) procedure or Current Procedural Terminology, 4th edition
codes for cholecystectomy from December 31, 2004 to December 31, 2010. Complex procedures and patients (eg, cancer, end-stage
renal disease) and procedures with pre-existing infection were excluded. Surgical site infections within 90 days after cholecystectomy
were identified by ICD-9-CM diagnosis codes. A Cox proportional hazards model was used to identify independent risk factors for
SSI.
Results. Surgical site infections were identified after 472 of 66 566 (0.71%) cholecystectomies; incidence was higher after open
(n = 51, 4.93%) versus laparoscopic procedures (n = 421, 0.64%; P < .001). Independent risk factors for SSI included male gender, preoperative chronic anemia, diabetes, drug abuse, malnutrition/weight loss, obesity, smoking-related diseases, previous Staphylococcus
aureus infection, laparoscopic approach with acute cholecystitis/obstruction (hazards ratio [HR], 1.58; 95% confidence interval
[CI], 1.27–1.96), open approach with (HR, 4.29; 95% CI, 2.45–7.52) or without acute cholecystitis/obstruction (HR, 4.04; 95% CI,
1.96–8.34), conversion to open approach with (HR, 4.71; 95% CI, 2.74–8.10) or without acute cholecystitis/obstruction (HR, 7.11;
95% CI, 3.87–13.08), bile duct exploration, postoperative chronic anemia, and postoperative pneumonia or urinary tract infection.
Conclusions. Acute cholecystitis or obstruction was associated with significantly increased risk of SSI with laparoscopic but not
open cholecystectomy. The risk of SSI was similar for planned open and converted procedures. These findings suggest that stratification by operative factors is important when comparing SSI rates between facilities.
Keywords. administrative health claims data; cholecystectomy; risk factors; surgical site infection.

Surgical site infection (SSI) is the most common healthcare-associated infection [1, 2] and contributes to increased length of
hospitalization and healthcare costs [1, 3]. Cholecystectomy is
the most commonly performed abdominal surgery and one of
the most common ambulatory procedures performed in the
United States [4, 5]. The incidence of SSI is higher after open
versus laparoscopic cholecystectomy, with reported SSI rates
after open cholecystectomy ranging from 1.1% to 8.4% [6–16]
versus 0.3% to 3.4% after laparoscopic cholecystectomy [6–16].
Although open cholecystectomy has been consistently associated with higher risk of SSI [6, 7, 10, 13, 17–19], other risk
factors for SSI have not been as well established. Older age [6,
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7, 18, 20, 21], male gender [6, 7, 13], longer duration of surgery [6, 13, 17, 18, 20], multiple surgical procedures [6, 20],
higher severity of illness [6, 8, 10, 17, 18], and contaminated/
infected wound class [6, 8, 17, 18] have been reported as independent risk factors for SSI after cholecystectomy. The impact
of other patient-, operative-, and postoperative-level factors
on SSI risk after cholecystectomy has not been well studied,
and it may be important for risk stratification in facilities with
different patient case mix. Because the majority of cholecystectomy operations are performed in ambulatory surgery, we
sought to investigate risk factors for SSI in patients without
serious underlying medical conditions after cholecystectomy
in a large, geographically diverse cohort of privately insured
persons.
METHODS
Primary Data Source

We conducted a retrospective cohort study using the
HealthCore Integrated Research Database, which includes
all fully adjudicated claims submitted for reimbursement
from providers, facilities, and outpatient pharmacies linked
to private health plan enrollment information, as described
previously [22].
Cholecystectomy SSI Risk Factors • OFID • 1
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evidence from other unique providers to determine the most
likely surgery date (Supplementary Appendix 1). After consolidating service dates, if there was still more than 1 claim date for
cholecystectomy within an individual person, we used the first
claim date as the study procedure date.
We classified the cholecystectomy as laparoscopic or open
based on ICD-9-CM procedure and CPT-4 codes from the provider and facility (Supplementary Appendix 1). As described
previously [22], to obtain more accurate SSI rates by surgical
approach, we excluded cholecystectomy procedures that were
coded by a provider- or facility-only, or when the provider and
facility coded discordant surgical approaches.

Exclusion of Erroneous Claims for Cholecystectomy

Identification of Surgical Site Infection

We excluded erroneous claims (ie, facility claims with apparent CPT-4, Healthcare Common Procedure Coding System, or
UB-04 revenue codes truncated to 4 digits and populated in the
fields reserved for ICD-9-CM procedure codes) as described
previously [22]. We also excluded claims in which a cholecystectomy procedure code was present only on 1 line on a single
claim, with no other claims on the same date.

Surgical site infections recorded 2–90 days after cholecystectomy were identified using ICD-9-CM diagnosis codes from
inpatient and outpatient facilities and provider claims. We did
not include claims with SSI diagnosis codes from service locations inconsistent with a provider diagnosis of SSI (eg, home,
ambulance) and claims with CPT-4 codes for laboratory services (88104-88399) to avoid “rule-out” diagnoses. Persons
with claims for SSI, peritonitis, retroperitoneal infection, or
septicemia (ICD-9-CM diagnosis 038.0–0.38.9, 790.7) between
30 days before to 1 day after the cholecystectomy date were
excluded due to pre-existing infection.
The diagnosis codes used to identify SSIs included postoperative wound infection (998.5, 998.51, 998.59), peritonitis (567.2–
567.29, 567.9), and retroperitoneal infection (567.3–567.39).
We also considered a diagnosis code of cellulitis of the trunk
(682.2) on the same claim as a CPT-4 code for incision and
drainage (10060, 10061, 10180, 11005, 49020, 49021, 49040,
49041, 49060, 49061) as evidence of SSI, consistent with the
NHSN definition of SSI [23]. The ICD-9-CM diagnosis code for
unspecified cellulitis (682.9) was also used to identify SSIs, but
only if it was on the same claim as an abdomen-specific CPT-4
code for incision and drainage (11005, 49020, 49021, 49040,
49041, 49060, 49061), or if it was coded on the same claim as
an incision and drainage procedure by the operating surgeon.
We defined the SSI onset date as described previously [25]. We
categorized SSIs as serious if they were coded during an inpatient admission or within 14 days of a laparotomy (ICD-9-CM
procedure 54.11, 54.12, 54.19; CPT-4 49000, 49002) or incision
and drainage procedure (as per codes defined above).
We identified SSIs up to 90 days after surgery, with earlier
censoring for the end of insurance enrollment or the day after
subsequent abdominal surgery. We excluded nonabdomen-specific ICD-9-CM diagnosis codes for SSI (eg, 998.59) if the code
was first recorded after a nonabdominal NHSN surgery. We
extended surveillance beyond the standard NHSN definition of
symptom onset within 30 days because an SSI is not detectable
in claims data until the patient presents for care, which could be
delayed from symptom onset. In addition, previous work has
shown that limiting identification of SSI to 30 days can miss

Exclusion of Complicated Patients and Procedures

Because our focus was on SSI risk in patients who would be eligible to have their procedure performed in ambulatory surgery,
we excluded cholecystectomy procedures performed in medically
complicated patients (ie, coded for cancer, chemotherapy, end-stage
renal disease, or prior organ transplant) from 30 days (365 for organ
transplant) before to 7 days after cholecystectomy (Supplementary
Appendix 1). We also excluded complex operations, defined as
those in which motor vehicle accident, fracture involving the skull
or trunk, abdominal compartment syndrome, or gunshot wound
were coded on the same claim as the cholecystectomy or on a
contemporaneous ambulance or emergency department claim,
and other complicated procedures, as defined in Supplementary
Appendix 1. We also excluded cholecystectomy procedures performed on the day of or after another surgical procedure during
the same hospitalization; additional surgical procedures were identified using the procedure codes used for SSI surveillance by the
National Healthcare Safety Network (NHSN) [23] and additional
CPT-4 codes for abdominal surgeries (Supplementary Appendix
1). We did not exclude a cholecystectomy if another procedure
occurred after the cholecystectomy, because these might have been
performed as a result of a complication of the cholecystectomy.
Finally, we excluded cholecystectomies performed on or after day 3
of an inpatient hospital stay because these patients would not have
had the opportunity for surgery in an ambulatory facility.
Surgery Date and Classification of Cholecystectomy

All provider and facility claims for cholecystectomy within
7 days were collapsed into a single surgery due to the potential
for inaccuracy in dates [24]. When there was more than one date
within 7 days coded for cholecystectomy, we compared facility and provider surgery dates and incorporated supplemental
2 • OFID • Warren et al
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We identified cholecystectomy procedures performed at a
hospital on an inpatient or outpatient basis or at a freestanding ambulatory surgery center (ASC) using International
Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) and Current Procedural Terminology, 4th edition (CPT-4) procedure codes from facility and provider claims
between December 31, 2004 and December 31, 2010 among
members aged 18–64 years (Supplementary Appendix 1). To
capture comorbidities, we excluded members lacking prescription drug coverage and/or 365 days of prior insurance enrollment before cholecystectomy.

Cholecystectomy Patient Population

a large proportion of infections, depending on the procedure
[26].
Identification of Risk Factors for Surgical Site Infection

Statistical Analysis

We used univariate and multivariable Cox proportional hazards
models to examine risk factors for SSI, and we accounted for
censoring before the 90-day follow-up period. For multivariable
models, backward selection was used with P < .05 as the cutoff
for inclusion among variables with P < .2 in univariate models.
We assessed multicollinearity by examining the tolerance values
in each model to ensure independence of explanatory variables. In
the event of multicollinearity, we considered model performance
(C-statistic) to determine which variable to use in the final model.
Post hoc testing was performed to determine whether related risk
factors had significantly different hazard ratios (HRs) in the multivariable model. As sensitivity analyses to determine the robustness
of our model, we developed models for early SSI (within 30 days of
surgery) and serious SSI. All data management and analyses were
performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
This study was approved by the Washington University Human
Research Protection Office with a waiver of informed consent.
RESULTS

A total of 160 817 cholecystectomy patients met initial eligibility criteria during the 7-year study period. The number of
patients was reduced to 66 566 after removing procedures
coded by either provider or facility alone (n = 10 738), procedures performed at the time of another abdominal operation
(n = 15 698), procedures performed after the second day of
hospitalization or at the same time or after another NHSN surgery (n = 14 232), procedures in medically complicated patients
(n = 5622), procedures with discordant coding for open versus
laparoscopic approach (n = 727), procedures performed at the
time of pre-existing infection (n = 753), and patients without
prescription drug coverage (n = 5204) or without 1 year of prior
insurance coverage (n = 41 277).
Over 98% of the cholecystectomy procedures were performed laparoscopically (65 532 of 66 566). Of the 1034 open
procedures, 499 were planned open procedures and 535 were
laparoscopic converted to open procedures. Seventy-five percent of operations were performed in females, and the median
age at time of surgery was 45 years (range 18–64). Persons who
had a laparoscopic procedure were more likely to be female
and younger than those with open cholecystectomy (P < .001).
Most operations were performed as same day surgery in a hospital (58%) or during an inpatient hospital admission (16%).
Planned open or converted procedures were more likely than
laparoscopic procedures to be performed during an inpatient
hospitalization (861 [83.3%] vs 15 586 [23.8%]; P < .001).
Four hundred seventy-two surgical site infections were identified after the 66 566 procedures (0.71%) (Table 1). Eighty-one
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We obtained patient age and sex from enrollment files. Patient
home zip code was matched to year 2000 census median household income [27] to determine income quartile and linked
to the 2006 National Center for Health Statistics (NCHS)
urban-rural classification scheme [28] through a 5-digit Federal
Information Processing Standard code to determine patient
urban-rural status.
Patient comorbidities and postoperative risk factors were
identified using ICD-9-CM diagnosis codes [29], ICD-9-CM/
CPT-4 procedure codes, and outpatient prescription drug
claims. All inpatient facility claims were included; we excluded
provider and outpatient facility claims containing only CPT-4
or UB-04 revenue codes for pharmacy, diagnostic radiology/
cardiology/pulmonology, clinical laboratory, physical/occupational therapy, speech pathology, or ambulance services, to
increase the likelihood that the diagnosis was assigned by a clinician. One or more inpatient claim(s) or ≥2 provider or outpatient facility claims from −365 to + 7 days after cholecystectomy
were required to establish the diagnosis of most comorbidities
(Supplementary Appendix 2) [30]. Postoperative risk factors
were restricted to those factors coded before SSI.
We included cholecystectomy-related diagnoses on the same
claim as the cholecystectomy procedure and concurrent procedures as potential operative risk factors (Supplementary
Appendix 2). Conversion to an open procedure was defined
based on the ICD-9-CM diagnosis code for laparoscopic to open
conversion in patients coded for open cholecystectomy; if the
provider and facility coded a laparoscopic cholecystectomy, we
assumed the conversion code referred to another procedure on
the same claim because the conversion diagnosis code is not specific to cholecystectomy.
We used the American Hospital Association (AHA) Annual
Survey of Hospitals (Health Forum, LLC, Chicago, IL) and the
Outpatient Surgery Center Profiling Solution data (IMS Health,
Plymouth Meeting, PA) to determine whether the cholecystectomy was performed at a hospital or freestanding ASC. These
sources were matched to the facility where the cholecystectomy
was performed using National Provider Identifier codes (when
available) or facility name and address fields. Among facilities
matching to a hospital in the AHA survey, determination of
inpatient or outpatient procedure was based on an inpatient
designation by the facility for admissions with length of stay
of 1 day or inpatient designation by the facility or provider for
admissions with length of stay greater than 1 day. Number of
beds, medical school affiliation, residency program, and ownership were captured from the AHA data for hospitals, whereas
number of surgical procedures, urban location of facility, and
region in the United States were available for hospitals and

ASCs. Urban-rural location of the facility was available in the
AHA data directly; we used the NCHS urban-rural classification scheme linked to ASC zip code for the IMS Health data.

Table 1.

Univariate Cox Proportional Hazards Model of Risk Factors for SSI After Cholecystectomya

Variable

Category

Total

SSI n (%)

No SSI n (%)

472

66 094

P

Hazards Ratio (95% CI)

Patient factors
Demographics
Age

19 (4.0)

4675 (7.1)

40 (8.5)

5742 (8.7)

1.71 (0.99–2.95)

31–35 years

53 (11.2)

6962 (10.5)

1.86 (1.10–3.14)

36–40 years

48 (10.2)

8160 (12.3)

1.44 (0.84–2.44)

41–45 years

49 (10.4)

9157 (13.9)

1.31 (0.77–2.22)

46–50 years

72 (15.3)

9604 (14.5)

1.83 (1.10–3.03)

51–55 years

73 (15.5)

9054 (13.7)

1.97 (1.19–3.26)

56–60 years

74 (15.7)

7800 (11.8)

2.31 (1.39–3.82)

61–64 years
Male

44 (9.3)

4940 (7.5)

167 (35.4)

16 609 (25.1)

.008

1.00

2.18 (1.27–3.73)
<.001

1.63 (1.35–1.97)

Comorbidities/Medications
Anticoagulopathy drugs

n < 10

437 (0.7)

.107

1.94 (0.87–4.34)

Blood loss anemia

13 (2.8)

660 (1.0)

<.001

2.80 (1.61–4.86)

Chronic anemia

36 (7.6)

1417 (2.1)

<.001

3.75 (2.67–5.27)

Congestive heart failure

22 (4.7)

1314 (2.0)

<.001

2.41 (1.57–3.70)

Depression

30 (6.4)

2953 (4.5)

.048

1.45 (1.00–2.10)

Diabetes mellitus

79 (16.7)

5835 (8.8)

<.001

2.07 (1.63–2.64)

318 (0.5)

<.001

3.98 (2.06–7.70)

Drug abuse

n < 10

Hypertension

191 (40.5)

21 795 (33.0)

Liver disease

11 (2.3)

617 (0.9)

.001

1.38 (1.15–1.66)

.002

2.52 (1.39–4.59)
2.44 (1.57–3.77)

Malnutrition/weight loss

21 (4.4)

1234 (1.9)

<.001

Obesity

82 (17.4)

7511 (11.4)

<.001

1.64 (1.29–2.08)

Peripheral vascular disease

n < 10

414 (0.6)

.005

2.72 (1.35–5.47)

Pneumonia or urinary tract infection

26 (5.5)

2208 (3.3)

.010

1.69 (1.14–2.51)

Psychoses

23 (4.9)

2139 (3.2)

.047

1.53 (1.01–2.33)

219 (0.3)

<.001

Renal failure

n < 10

Smoking

74 (15.7)

8538 (12.9)

Smoking-related diseases

39 (8.3)

Staphylococcus aureus infection

n < 10

5.18 (2.58–10.43)

.073

1.26 (0.98–1.61)

2371 (3.6)

<.001

2.42 (1.74–3.36)

85 (0.1)

<.001

6.56 (2.45–17.55)

Operative Factors
Facility
Type of facility

Number of beds

Medical school affiliation

Inpatient hospital

166 (35.2)

10 798 (16.3)

Outpatient hospital

188 (39.8)

38 711 (58.6)

20 (4.2)

4038 (6.1)

0.32 (0.20–0.51)

Missing facilityb or uncertain inpatient
designationc

98 (20.8)

12 547 (19.0)

0.51 (0.40–0.65)

253 (53.6)

32 714 (49.5)

300–499

1–299

81 (17.2)

13 508 (20.4)

0.78 (0.60–1.00)

500+

62 (13.1)

8728 (13.2)

0.92 (0.70–1.21)

ASC

20 (4.2)

4038 (6.1)

0.64 (0.41–1.01)

Missing facilityb

56 (11.9)

7106 (10.8)

Yes

175 (37.1)

22 267 (33.7)

No

221 (46.8)

32 683 (49.4)

20 (4.2)

4038 (6.1)

Missing facilityb

Ownership

56 (11.9)

7106 (10.8)

Yes

142 (30.1)

17 126 (25.9)

No

.121

1.00

1.02 (0.77–1.37)
.140

1.16 (0.95–1.42)
1.00
0.73 (0.46–1.16)
1.17 (0.87–1.57)

.063

1.23 (1.00–1.52)

254 (53.8)

37 824 (57.2)

1.00

ASC

20 (4.2)

4038 (6.1)

0.74 (0.47–1.17)

Missing facilityb

56 (11.9)

7106 (10.8)

Government

49 (10.4)

5594 (8.5)

303 (64.2)

42 194 (63.8)

0.82 (0.61–1.11)

Nongovernment, not for profit

4 • OFID • Warren et al

1.00
0.32 (0.26–0.39)

ASC

ASC
Residency program

<.001

1.18 (0.88–1.57)
.178

1.00

Investor owned, for profit

44 (9.3)

7162 (10.8)

0.70 (0.47–1.05)

ASC

20 (4.2)

4038 (6.1)

0.57 (0.34–0.95)

Missing facilityb

56 (11.9)

7106 (10.8)

0.90 (0.62–1.33)
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18–25 years
26–30 years

Table 1.

Continued

Variable

Category

SSI n (%)

No SSI n (%)

P

Hazards Ratio (95% CI)

Cholecystectomy
Acute cholecystitis/obstruction

205 (43.4)

17 481 (26.4)

<.001

2.13 (1.78–2.56)

Other/chronic cholecystitis

386 (81.8)

56 202 (85.0)

.047

0.79 (0.62–1.00)
2.03 (1.45–2.84)

Choledocholithiasis
Surgical approach

2652 (4.0)

<.001

65 111 (98.5)

<.001

Laparoscopic converted to open approach

28 (5.9)

507 (0.8)

Planned open approach

1.00
8.48 (5.79–12.44)

23 (4.9)

476 (0.7)

Endoscopic retrograde
cholangiopancreatography

n < 10

302 (0.5)

<.001

3.74 (1.86–7.52)

7.40 (4.87–11.26)

Bile duct exploration

12 (2.5)

426 (0.6)

<.001

3.97 (2.24–7.04)

Chronic anemia

33 (7.0)

1289 (2.0)

<.001

3.76 (2.64–5.35)

Pneumonia or urinary tract infection

28 (5.9)

1386 (2.1)

<.001

2.91 (1.99–4.27)

Postoperative Factors

Abbreviations: ASC, ambulatory surgery center; CI, confidence interval; SSI, surgical site infection.
a
The following factors had P ≥ 0.2 and were excluded from the table: patient home urban/rural location, patient income quartile, alcohol abuse, cancer, coagulopathy, disease-modifying
antirheumatic drugs or biologic drugs, oral corticosteroids, skin disease, total annual surgical procedures quartile for performing facility, facility urban/rural location, facility region of the
United States, cholelithiasis, cholangiography, and other bile duct procedures.
b
Missing facility type due to no match to a facility in the American Hospital Association Annual Survey of Hospitals or the IMS Health Outpatient Surgery Center Profiling Solution data or
a match to multiple facilities.
c

Uncertain inpatient hospital admission due to inpatient designation based on a same-day nonfacility claim.

percent of SSIs were first identified 2–30 days postsurgery,
12.9% between 31–60 days, and 5.7% between 61–90 days after
the procedure. The incidence of SSI was significantly higher
Table 2.

after an open (4.93% [51 of 1034]) versus laparoscopic cholecystectomy (0.64% [421 of 65 532]; P < .001). Overall, 63.1% of
SSIs were serious. There was no significant difference between

Multivariable Cox Proportional Hazards Model of Significant Risk Factors for SSI After Cholecystectomy

Variable

Category

Adjusted Hazards Ratio (95% CI)

Patient Risk Factors
Male

1.42 (1.17–1.72)

Chronic anemia

2.46 (1.67–3.63)

Diabetes mellitus

1.53 (1.19–1.98)

Drug abuse

2.85 (1.46–5.54)

Malnutrition/weight loss

2.09 (1.34–3.25)

Obesity

1.39 (1.09–1.77)

Smoking-related diseases

1.63 (1.16–2.28)

Staphylococcus aureus infection

3.43 (1.26–9.31)

Operative Risk Factors
Type of facility

Inpatient hospital

1.00

Outpatient hospital

Surgical approach and acute cholecystitis/
obstruction

0.57 (0.45–0.74)

ASC

0.65 (0.40–1.05)

Missing facility or uncertain inpatient hospital designationa

0.81 (0.62–1.06)

Laparoscopic approach without acute cholecystitis/obstruction

1.00

Laparoscopic approach with acute cholecystitis/obstruction

1.58 (1.27–1.96)

Laparoscopic converted to open approach without acute
cholecystitis/obstruction

7.11 (3.87–13.08)

Laparoscopic converted to open approach with acute
cholecystitis/obstruction

4.71 (2.74–8.10)

Planned open approach without acute cholecystitis/
obstruction

4.04 (1.96–8.34)

Planned open approach with acute cholecystitis/obstruction
ERCP/bile duct explorationb

4.29 (2.45–7.52)
2.08 (1.31–3.30)

Postoperative Risk Factors (Before SSI)
Chronic anemia

1.68 (1.12–2.53)

Pneumonia or urinary tract infection

2.15 (1.45–3.17)

Abbreviations: ASC, ambulatory surgery center; CI, confidence interval; ERCP, endoscopic retrograde cholangiopancreatography; SSI, surgical site infection.
a
Missing facility type due to no match to a facility in the American Hospital Association Annual Survey of Hospitals or the IMS Health Outpatient Surgery Center Profiling Solution data or a
match to multiple facilities. Uncertain inpatient admission due to inpatient designation based on a same-day nonfacility claim.
b

ERCP and bile duct exploration combined for multivariable model due to small cell counts.
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37 (7.8)
421 (89.2)

Laparoscopic approach
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DISCUSSION

There are few published data on risk factors for SSI after cholecystectomy, particularly after ambulatory procedures. Our
study identifies new patient-, operative-, and postoperative risk
factors for infection after cholecystectomy to the literature and
confirms some risk factors identified in previous reports.
We found a 6-fold higher risk of SSI after open versus laparoscopic cholecystectomy, consistent with previous findings
[6–16]. The incidence of SSI after laparoscopic cholecystectomy
converted to an open procedure was the same as the SSI incidence after planned open cholecystectomy (5.23% and 4.61%,
respectively). This contrasts with the finding of Bogdanic
et al [13] who reported a higher SSI rate after laparoscopic to
open conversion (17.9%) compared with open (6.1%) surgery,
although only 28 operations in that study involved conversion.
Two groups reported significantly increased risk of SSI after
conversion from laparoscopic to open procedure compared
with laparoscopic cholecystectomy, but neither study included
planned open procedures [20, 31]. Our results suggest that
in the present era, uncomplicated patients undergoing either
planned or converted open cholecystectomy are at similar risk
of SSI.
We found that acute cholecystitis or obstruction was associated
with increased risk of surgical site infection after laparoscopic but
not after open (planned or converted) cholecystectomy. This contrasts with the finding of Hussain and Khan [32] who reported
no difference in the incidence of SSI in laparoscopic cholecystectomy patients in Saudi Arabia with acute versus chronic cholecystitis (1.7% and 1.3%, respectively). In other studies restricted
to laparoscopic cholecystectomy, Giger et al [33] found increased
risk of postoperative local and systemic complications (including SSI) with acute cholecystitis in multivariate analyses, whereas
den Hoed et al [34] found an association in univariate analysis
between acute cholecystitis and increased risk of SSI.
At the patient level, we found gender, chronic anemia, diabetes, drug abuse, malnutrition/weight loss, obesity, smokingrelated diseases, and previous S aureus infection to be associated
with increased risk of SSI. With the exception of diabetes [7],
malnutrition [35], and male (vs female) gender [6, 7, 13], none of
these conditions have been previously reported as independent
risk factors for SSI after cholecystectomy. Men have also been
shown to be at increased risk of conversion to open procedure
[36–38] and intraoperative and postoperative local complications after cholecystectomy [33, 39]. In our study, men had more
severe biliary disease compared with women, including higher
proportions of men with acute cholecystitis or obstruction,
choledocholithiasis, and open (planned or converted) operative approach (see Supplementary Appendix 3; data not shown).
It is possible that the increased risk of SSI we found in men is
due to residual confounding with increased severity of biliary
tract disease that we were unable to completely capture with the
claims data.
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the proportion of serious SSIs that were early (within 30 days
of surgery) compared with nonserious SSIs (83.9% [250 of 298]
vs 77.0% [134 of 174], respectively; P = .064). Infection rates
were similar for planned open and converted-to-open procedures (4.61% [23 of 499] and 5.23% [28 of 535], respectively;
P = .643).
Univariate risk factors for SSI are noted in Table 1. For
the multivariable analysis, an interaction term was included
in the model to analyze the impact of acute cholecystitis/
obstruction depending on the operative approach (Table 2).
Patient-level risk factors for SSI included male gender,
chronic anemia, diabetes mellitus, drug abuse, malnutrition/weight loss, obesity, smoking-related diseases (eg, lung
cancer, chronic obstructive pulmonary disease), and previous Staphylococcus aureus infection. Patients whose cholecystectomy was performed as an outpatient procedure at a
hospital (HR 0.57) were at lower risk of SSI. Laparoscopic
approach with acute cholecystitis/obstruction was associated with significantly increased risk of SSI compared with
laparoscopic approach without acute cholecystitis (HR 1.58).
Open cholecystectomy was associated with increased risk of
SSI regardless of whether acute cholecystitis/obstruction was
present (HR 4.29 and 4.04, respectively; P = .891 for post
hoc comparison of the HRs). Conversion to open cholecystectomy was also associated with similar risk of SSI, regardless of whether acute cholecystitis/obstruction was present
(HR 4.71 and 7.11, respectively; post hoc P = .283). In addition, the HRs for SSI for planned open compared with converted procedures were similar among those with (P = .796)
and without (P = .217) acute cholecystitis/obstruction.
Concurrent endoscopic retrograde cholangiopancreatography (ERCP)/bile duct exploration, postoperative chronic
anemia, and postoperative pneumonia/urinary tract infection were also associated with significantly higher risk of SSI
post-cholecystectomy.
In a sensitivity analysis comparing early SSI only versus no
SSI, risk factors were generally similar to the original model.
Previous S aureus infection, ERCP/bile duct exploration, and
postoperative chronic anemia dropped out of the model and
were among the factors with the smallest number of patients
with SSI. The general trends and magnitude of HRs in the early
SSI model were similar to the total SSI model, and in all cases
the HRs in the early SSI model were within the 95% confidence
interval of the HR from the total SSI model.
In the second sensitivity analysis restricting the outcome to
serious SSI versus no SSI, new risk factors included older age
and choledocholithiasis. Obesity, smoking-related diseases, and
ERCP/bile duct exploration were dropped from the model. The
general trends and magnitude of HRs in the serious SSI model
were similar to the total SSI model, and in all cases the HRs in
the serious SSI model were within the 95% confidence interval
of the HR from the total SSI model.

CONCLUSIONS

The SSI risk factors we identified after cholecystectomy may be
helpful for risk stratification to adjust for differences in patient
mix between different facilities. This is important when comparing SSI rates between institutions, because facilities may have differing proportions of complex cases requiring an open approach
and patients with more severe gallbladder disease. Failure to
account for this complexity in case mix may result in misclassifying institutions as having a higher than expected rate of infection
after cholecystectomy. In the current era of pay-for-performance
and publicly reported healthcare-associated infection rates,
this could have considerable negative impact for providers and
facilities. Most importantly, understanding the relevant perioperative risk factors for infection will better inform patients and
healthcare providers what to anticipate after this common surgical procedure and may allow targeted interventions in high-risk
groups to reduce postoperative infections.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
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